dulaglutide
dulaglutide: developed by 1 company · 5 clinical trials tracked · 1 FDA decision.
dulaglutide evidence translation
What we can confirm
1 FDA record · 5 tracked trials
What it means
What to watch
Prepared research question
How could dulaglutide → LLY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (2)
| Company | Phase |
|---|---|
| ELI LILLY & Co (LLY) For the treatment of type 2 diabetes in adults and pediatric… | Approved |
| ELI LILLY & Co (LLY) Type 2 Diabetes Mellitus (T2DM); Type 2 Diabetes Mellitus; D… | Phase 4 |
Clinical Trials (5)
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes
Primary endpoint: Change from Baseline in Hemoglobin A1c (HbA1c)
Comparative Effectiveness of Dulaglutide, Semaglutide, and Tirzepatide in Preventing Cardiovascular Events in Patients With Type 2 Diabetes and Obesity With or Without Atherosclerotic Cardiovascular Disease.
Primary endpoint: Composite of myocardial infarction, stroke, or all-cause mortality.
A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Dulaglutide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes Mellitus
Primary endpoint: Percentage of Fasting Participants with Lack of Gastric Content Retention Post-Solid Test Meal
A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus
Primary endpoint: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Primary endpoint: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]
FDA Decisions1 records
Frequently asked questions
Who is developing dulaglutide?
dulaglutide is being developed by ELI LILLY & Co.
How many clinical trials involve dulaglutide?
BioSniper tracks 5 clinical trials involving dulaglutide.
What is dulaglutide's latest FDA decision?
The most recent tracked FDA decision for dulaglutide is Approval, dated September 18, 2014.